IGH (Immunoglobulin Heavy Locus)

This case of WM with renal AHL amyloidosis highlights the importance of keeping renal amyloidosis in mind in patients with proteinuria. The favourable hematologic and renal response to treatment with bendamustine and rituximab in this case adds valuable data for the management of WM complicated by renal amyloidosis.

P2/3, N=456, Not yet recruiting, Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Time-limited BR-VR achieved high uMRD rates and durable remissions with a manageable safety profile. While the treatment landscape in CLL has largely shifted toward chemotherapy-free regimens, these data demonstrate the biological proof-of-concept that limited induction chemotherapy can effectively mitigate TLS risk and facilitate safe outpatient ramp-up of venetoclax.

CLL in Türkiye demonstrates region-specific immunogenetic features while preserving established clinico-biological correlations. Integration of IGHV status, cytogenetics, and BCR stereotypy may improve risk stratification in underrepresented populations.

P3, N=420, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Trial completion date: Aug 2033 --> Apr 2032 | Trial primary completion date: Nov 2032 --> Aug 2031

Notably, the rate of clonal IGH gene rearrangements was significantly different between heavy-chain and light-chain only MM groups. This is the first study in Vietnamese MM patients to comprehensively describe the characteristics of IG gene rearrangements.

A 67-year-old man was diagnosed with EBV-positive DLBCL 17 years ago and achieved a sustained remission following six cycles of R-CHOP therapy...These findings suggest that PBL originated through expansion of a pre-existing minor subclone that persisted since the initial DLBCL diagnosis, driven by long-term clonal dynamics. Our case highlights the potential utility of immunoglobulin repertoire analysis in identifying clonal relationships among lymphomas, supporting treatment decisions, and understanding the pathogenesis of secondary lymphomas.

P1, N=15, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Mar 2028 --> Jul 2028

The MONSTAR3 hematology cohort represents the first nationwide integrated multi-omics initiative dedicated to hematologic malignancies. Its large scale, standardized biospecimen framework, and capacity to incorporate emerging technologies provide a robust infrastructure for molecular stratification, longitudinal disease monitoring, and hypothesis-driven interventional research, thereby advancing clinically actionable precision hematology.

Our analyses show that more epigenetic states are present among CLL neoplasms than are captured by the clinical classification system. Our approach can be used to generate continuous metrics of epigenetic states for other neoplasms.

Objective: This study aimed to investigate the clinical significance of measurable residual disease (MRD) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) regimen. Furthermore, the ibrutinib maintenance strategy can be adjusted based on the BM-MRD level at 2 years. Monitoring PB-MRD dynamically was crucial in detecting MRD conversion and progression.

Antifungal therapy with amphotericin B combined with voriconazole was administered, along with symptomatic and immunomodulatory treatments...This case suggests that in adult patients with diffuse skin lesions and systemic inflammatory reactions, if accompanied by multiple lymph node enlargements and pathological findings of cutaneous lymphadenitis, potential immune deficiencies related to anti-IFN-γ autoantibodies should be considered. For adults with unexplained lymphadenopathy accompanied by fungal infection, testing for anti-interferon-γ autoantibodies is recommended to identify potential underlying immune abnormalities and to inform subsequent individualized immunological assessment and therapeutic decision-making.